Y. Tomura

发表

Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist

T. Sugimoto, M. Saito, J. Tsukada, 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

In vivo visualization of characteristics of renal microcirculation in hypertensive and diabetic rats.

F. Kajiya, H. Tanaka, T. Yamamoto, 2001, American journal of physiology. Renal physiology.

Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs.

Y. Arai, J. Tsukada, A. Tahara, 2002, Pharmacological research.

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure.

K. Honda, J. Tsukada, W. Uchida, 1999, European journal of pharmacology.

Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats

K. Hayashi, T. Ishikawa, Masaki Abe, 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

Antifibrotic Effects of Pirfenidone in Rat Proximal Tubular Epithelial Cells

A. Tahara, Y. Tomura, K. Takakura, 2012, Renal failure.

Direct in vivo visualization of glomerular microcirculation by intravital pencil lens-probe CCD videomicroscopy.

F Kajiya, Y Ogasawara, F. Kajiya, 2000, Clinical hemorheology and microcirculation.

Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs.

T. Takenaka, J. Tsukada, W. Uchida, 1997, European journal of pharmacology.

Vasopressin regulates rat mesangial cell growth by inducing autocrine secretion of vascular endothelial growth factor

M. Shibasaki, J. Tsukada, A. Tahara, 2011, The Journal of Physiological Sciences.

Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction.

Y. Arai, J. Tsukada, A. Tahara, 2002, European journal of pharmacology.

Binding and Signal Transduction Characteristics of the Nonpeptide Vasopressin V1A Receptor-Selective Antagonist YM218 in Cultured Rat Mesangial Cells

K. Momose, M. Shibasaki, J. Tsukada, 2006, Pharmacology.

Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist.

M. Shibasaki, J. Tsukada, W. Uchida, 2005, Vascular pharmacology.

Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.

M. Shibasaki, J. Tsukada, W. Uchida, 2005, Pharmacological research.

Effects of YM471, a nonpeptide AVP V1A and V2 receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells

J. Tsukada, W. Uchida, A. Tanaka, 2001, British journal of pharmacology.

Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist.

J. Tsukada, W. Uchida, A. Tanaka, 2002, European journal of pharmacology.

Pharmacological Profile of YM 087 , A Novel Potent Nonpeptide Vasopressin V 1 A and V 2 Receptor Antagonist , in Vitro and in Vivo

M. Takanashi, J. Tsukada, W. Uchida, 1997 .

clinically-used ARBs: drug-target interaction analyses

M. Orita, Tomohiko Yamaguchi, H. Masuzaki, 2014 .

Effect of YM471, an orally active non-peptide arginine vasopressin receptor antagonist, on human vascular smooth muscle cells

J. Tsukada, W. Uchida, A. Tanaka, 2002, Journal of hypertension.

Distinct Properties of Telmisartan on Agonistic Activities for Peroxisome Proliferator-Activated Receptor γ among Clinically Used Angiotensin II Receptor Blockers: Drug-Target Interaction Analyses

M. Orita, Tomohiko Yamaguchi, H. Masuzaki, 2014, The Journal of Pharmacology and Experimental Therapeutics.

EFFECTS OF ATRIAL NATRIURETIC PEPTIDE ON PHENYLEPHRINE‐INDUCED RENIN RELEASE IN DOGS

H. Hisa, S. Satoh, Y. Tomura, 1990, Clinical and experimental pharmacology & physiology.

Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells

J. Tsukada, W. Uchida, A. Tanaka, 2000, British journal of pharmacology.

Atrial natriuretic factor suppresses neural stimulation of renin release in dogs.

H. Hisa, S. Satoh, Y. Tomura, 1989, The American journal of physiology.

Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy.

M. Shibasaki, J. Tsukada, A. Tahara, 2007, Vascular pharmacology.

Alterations of Renal Vasopressin V1A and V2 Receptors in Spontaneously Hypertensive Rats

J. Tsukada, W. Uchida, A. Tanaka, 2003, Pharmacology.

Characterization of rodent liver and kidney AVP receptors: pharmacologic evidence for species differences

J. Tsukada, W. Uchida, A. Tanaka, 1999, Regulatory Peptides.

PHARMACOLOGICAL PROFILE OF ORALLY ADMINISTERED YM087, A VASOPRESSIN ANTAGONIST, IN CONSCIOUS RATS

J. Tsukada, W. Uchida, A. Tahara, 1999, Clinical and experimental pharmacology & physiology.

Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells

T. Sugimoto, M. Saito, J. Tsukada, 1998, British journal of pharmacology.

Characterization of vasopressin receptor in rat lung

J. Tsukada, W. Uchida, A. Tanaka, 1998, Neuropeptides.

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.

J. Tsukada, W. Uchida, A. Tanaka, 1998, Cardiovascular research.

Binding Characteristics of YM087, an AVP Receptor Antagonist, in Rhesus Monkey Liver and Kidney Membranes

J. Tsukada, W. Uchida, A. Tanaka, 1998, Peptides.

microcirculation in hypertensive and diabetic rats In vivo visualization of characteristics of renal

F. Kajiya, Tokunori Yamamoto, Y. Tomura, 2016 .

Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells.

K. Momose, M. Shibasaki, J. Tsukada, 2006, European journal of pharmacology.

Effects of High Glucose on AVP-Induced Hyperplasia, Hypertrophy, and Type IV Collagen Synthesis in Cultured Rat Mesangial Cells

M. Shibasaki, J. Tsukada, A. Tahara, 2012, Endocrine research.

Comparison of vasopressin binding sites in human uterine and vascular smooth muscle cells.

J. Tsukada, W. Uchida, A. Tanaka, 1999, European journal of pharmacology.

AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V1A or V1B receptors

T. Sugimoto, M. Saito, J. Tsukada, 1999, Pflügers Archiv.

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells.

J. Tsukada, W. Uchida, A. Tanaka, 1997, Journal of cardiovascular pharmacology.

Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis.

T. Noto, Y. Tomura, K. Takakura, 2014, European journal of pharmacology.

VASOPRESSIN STIMULATES THE PRODUCTION OF EXTRACELLULAR MATRIX BY CULTURED RAT MESANGIAL CELLS

M. Shibasaki, J. Tsukada, A. Tahara, 2008, Clinical and experimental pharmacology & physiology.

Effect of vasopressin on type IV collagen production in human mesangial cells

M. Shibasaki, J. Tsukada, A. Tahara, 2008, Regulatory Peptides.

Original Research: Potential of urinary nephrin as a biomarker reflecting podocyte dysfunction in various kidney disease models

M. Eguchi, T. Mimura, H. Moritani, 2016, Experimental biology and medicine.

Direct in vivo Visualization of Renal Microcirculation by Intravital CCD Videomicroscopy

F. Kajiya, Tokunori Yamamoto, Y. Tomura, 2001, Nephron Experimental Nephrology.

Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.

M. Takanashi, J. Tsukada, W. Uchida, 1997, The Journal of pharmacology and experimental therapeutics.

Synthesis and pharmacological evaluation of 1-isopropyl-1,2,3,4-tetrahydroisoquinoline derivatives as novel antihypertensive agents.

M. Okada, M. Ohta, S. Tsukamoto, 2011, Chemical & pharmaceutical bulletin.

Downregulation of vasopressin V1A receptors and activation of mitogen‐activated protein kinase in rat mesangial cells cultured under high‐glucose conditions

M. Shibasaki, J. Tsukada, A. Tahara, 2012, Clinical and experimental pharmacology & physiology.

Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells

J. Tsukada, W. Uchida, A. Tanaka, 2002, Peptides.

Vasopressin induces human mesangial cell growth via induction of vascular endothelial growth factor secretion

M. Shibasaki, J. Tsukada, A. Tahara, 2011, Neuropeptides.

Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells.

M. Saito, J. Tsukada, W. Uchida, 1999, European journal of pharmacology.

Vasopressin increases type IV collagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells.

M. Shibasaki, J. Tsukada, A. Tahara, 2008, Pharmacological research.

Synthesis and pharmacological evaluation of 1-alkyl-N-[(1R)-1-(4-fluorophenyl)-2-methylpropyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents.

M. Okada, M. Ohta, S. Tsukamoto, 2011, Chemical & pharmaceutical bulletin.

Synthesis and pharmacological evaluation of 2-(1-alkylpiperidin-4-yl)-n-[(1r)-1-(4-fluorophenyl)-2-methylpropyl]acetamide Derivatives as Novel Antihypertensive Agents.

M. Okada, M. Ohta, S. Tsukamoto, 2012, Chemical & pharmaceutical bulletin.

Synthesis and pharmacological evaluation of 1-alkyl-N-[2-ethyl-2-(4-fluorophenyl)butyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents.

M. Okada, M. Ohta, S. Tsukamoto, 2011, Bioorganic & medicinal chemistry.

Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats

K. Hayashi, T. Ishikawa, Masaki Abe, 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

Therapeutic effects of interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 on diabetic nephropathy in type 2 diabetic mice

K. Hayashi, T. Ishikawa, M. Kondo, 2020, Naunyn-Schmiedeberg's Archives of Pharmacology.

Effect of YM-254890, a specific Galphaq/11 inhibitor, on experimental peripheral arterial disease in rats.

M. Taniguchi, H. Takamatsu, K. Miyata, 2006, European journal of pharmacology.

Effects of alpha adrenoceptor blockade on renal nerve stimulation-induced norepinephrine release and vasoconstriction in the dog kidney.

S. Araki, Y. Hayashi, H. Hisa, 1989, The Journal of pharmacology and experimental therapeutics.

Progression of renal failure with anaemia and multiple effects of angiotensin-converting enzyme inhibitor in rats with renal mass reduction.

A. Fujimori, K. Hayashi, M. Tanahashi, 2003, Pharmacological research.

Effects of C-type natriuretic peptide on renal vasoconstriction in dogs.

K. Yoshida, M. Yoshida, M. Suzuki‐Kusaba, 1997, European journal of pharmacology.

Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.

M. Orita, J. Tsukada, A. Kakefuda, 2006, Bioorganic & medicinal chemistry.

Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.

J. Tsukada, A. Tanaka, Y. Shimada, 2005, Chemical & pharmaceutical bulletin.

Distinct Properties of Telmisartan on Agonistic Activities for Peroxisome Proliferator-Activated Receptor γ among Clinically Used Angiotensin II Receptor Blockers: Drug-Target Interaction Analyses

M. Orita, Tomohiko Yamaguchi, H. Masuzaki, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Effects of atrial natriuretic peptide on adrenergically induced norepinephrine release and vasoconstriction in the dog kidney.

H. Hisa, S. Satoh, Y. Tomura, 1991, European journal of pharmacology.